{"title":"Polymorphism of the seventh component of complement (C7) in a healthy caucasian population: An immunoblotting study with neuraminidase-treated samples","authors":"G Dewald","doi":"10.1016/0769-2625(88)90096-7","DOIUrl":null,"url":null,"abstract":"<div><p>Genetic polymorphism of the seventh component of complement (C7) was studied in a healthy Caucasian population using polyacrylamide gel isoelectric focusing of neuraminidase-treated plasma samples and an immunoblotting procedure for the specific detection of C7. Among 248 blood donors, three C7-3/1 heterozygotes were identified, resulting in a C7<sup>∗</sup>3 allele frequency of 0.0061 ± 0.0035. Neuraminidase treatment of serum or plasma samples is necessary for unequivocal identification of C7<sup>∗</sup>3, which is known to be a hypomorphic variant. This observation is discussed with special reference to previous studies on C7 polymorphism in Caucasian populations, where untreated samples have been used for C7 typing.</p></div>","PeriodicalId":77665,"journal":{"name":"Annales de l'Institut Pasteur. Immunology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1988-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0769-2625(88)90096-7","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales de l'Institut Pasteur. Immunology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/0769262588900967","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3
Abstract
Genetic polymorphism of the seventh component of complement (C7) was studied in a healthy Caucasian population using polyacrylamide gel isoelectric focusing of neuraminidase-treated plasma samples and an immunoblotting procedure for the specific detection of C7. Among 248 blood donors, three C7-3/1 heterozygotes were identified, resulting in a C7∗3 allele frequency of 0.0061 ± 0.0035. Neuraminidase treatment of serum or plasma samples is necessary for unequivocal identification of C7∗3, which is known to be a hypomorphic variant. This observation is discussed with special reference to previous studies on C7 polymorphism in Caucasian populations, where untreated samples have been used for C7 typing.